Siltuximab

Phase 2

Johnson & Johnson (JNJ)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Multicentric Castleman's Disease

View Full Landscape

Drug Information

Target Indication

Multicentric Castleman's Disease

Clinical Trial

NCT01400503

Last updated: 5/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/22/2014

Sylvant

Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Accelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

levofloxacinPhase 3

Pneumonia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts